In COVID-19 news, the FDA has authorized updated boosters for younger children. The FDA also approved an at-home heart failure therapy, but issued a CRL for a Parkinson’s therapy. The agency has assigned PDUFDA dates for several BLA, including a hemophilia A gene therapy and Eylea for retinopathy in…
The Batten Disease Treatment Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and
U.S. diverts travelers from Uganda for health screenings due to Ebola outbreak; Former J&J executive Mathai Mammen emerges as top Biogen CEO candidate; Walgreens to begin selling over-the-counter hearing aids.
The Daily NewsAs per DelveInsight s assessment globally about 20 key pharma and biotech companies are working on 30 pipeline drugs in the Hereditary Angioedema therapeutics landscape based on different Routes of Administration RoA Mechanism of Action MoA and molecule types Several ...
<p><span>With help from Biomedtracker, <em>Scrip</em> takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important…
The Daily NewsGene therapy is a sophisticated procedure that involves the introduction of a gene to cure a variety of chronic conditions such as cancer or gene
DUBLIN--(BUSINESS WIRE)--Oct 11, 2022--
The Daily NewsWelcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Zoom can only go so far. That’s the mindset John Carr…
Endpoints NewsBiopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
“Delveinsight Business Research LLP”As per DelveInsight’s assessment, globally, about 35+ key pharma and biotech companies are working on 45+ pipeline
Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
New Jersey, USA,- The Worldwide Enzyme Replacement Therapy Market analysis by Market Research I
Tralesinidase alfa, a therapy candidate for Sanfilippo syndrome type B now in clinical trials, showed promise in a dog model of the disease.
The Colby Echo News<p>Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.</p>
The Colby Echo NewsBaker Brothers’ 13F portfolio value increased from $17.40B to $17.63B in Q2. Click here to read the portfolio’s Q2 2022 Update.
The Colby Echo NewsRare Disease Drug Market Overview Rare Disease Drug Market Report offers the latest industry insight
/PRNewswire/ -- The European Commission’s approval of a novel gene therapy for severe hemophilia A has paved the way for use of a companion diagnostic in the...
PharmiWeb.comGlobal Batten Disease Treatment Market by MarketsandResearch.biz provides insight into the current t
The Global Duchenne Muscular Dystrophy Treatment market is thoroughly studied in the report, with th
Enzyme Replacement Therapy Market research report is a high-quality report having in-depth market research studies. This market report provides the best
